The spring comes, the students return, and the tiger is powerful!!!
Huge benefits at the beginning of the year, limited time promotion! Thanks to the strong support of new and old users,
From March 7 to April 30, Meige biology carried many scientific research reagents for limited time and huge benefit promotion,
Sufficient spot supply, welcome to consult and order!

The body's immune system may find and destroy cancer cells. But cancer cells can be smart and develop skills to escape the immune system. Cold Spring Harbor Laboratory Professor Douglas Fearon and his postdoctoral Wang Zhikai discovered such a trick. Cancer cells weave inactivation signals into a protective armor that separates T cells that would otherwise kill them. This immune inactivation pathway provides a promising new treatment for pancreatic cancer, breast cancer and colorectal cancer.

Oxdx was born in Oxford University, UK. It is a technology company that uses super-resolution microscope and machine learning to build real-time pathogen testing system. Recently, oxdx has raised £ 2.6 million in seed funding for its AI driven machine learning diagnostic technology, which can identify and identify specific species and virus strains of bacteria and other pathogens in a sample in seconds. This initial fund is jointly invested by IQ capital and ahren innovation capital with the participation of science creates ventures. It will be used to expand the team and further verify the AI technology with development partners.

Single cell RNA sequencing, or scrna SEQ for short, is a technology that allows scientists to study gene expression in single cells in a mixed population, which is the way all cells exist in human tissues.

Researchers at Karolinska college in Sweden used a technique called spatial transcriptomics (st) to analyze gene expression in the mouse colon and drew a map showing the expression location of a single gene in the tissue. When they superimposed previously known human transcriptional data on the map, the researchers had a new understanding of inflammatory bowel disease (IBD).

Research led by WSU scientists at Washington State University supports a new theory that people's innate immune system can respond differently to specific pathogens. This quality, called immune specificity, was previously attributed only to the adaptive immune system, which develops through disease over time.

CRISPR gene editing technology has become a powerful tool to knock out or change DNA sequences and study the resulting effects. Now, researchers at the Gladstone Institute and UCSF at the University of California, San Francisco have chosen the CRISPR cas9 system to forcibly activate genes in human immune cells rather than edit them. This method, called crispra, CRISPR activation, allows them to find genes that play a role in immune cell biology more thoroughly and faster than before.

Gram negative bacteria such as Acinetobacter baumannii, Pseudomonas aeruginosa and Klebsiella pneumoniae are all listed in the WHO priority pathogen list, and new treatment options are urgently needed. One of the main reasons why these organisms are so difficult to treat is that they are surrounded by an outer membrane (OM) as an impermeable barrier to prevent antibiotics from reaching targets in bacteria. Therefore, polymyxin, which can be obtained clinically as polymyxin B (PMB) and polymyxin E, is considered to be the last-line therapy for the treatment of antimicrobial resistant gram-negative organisms. Polymyxin initially binds to lipopolysaccharide (LPS) located in the outer lobule of gram-negative bacterium OM, causing considerable om disintegration and eventually cell death. However, the global reports of polymyxin resistance have increased, threatening the effectiveness of these important antibiotics. At present, only a few new antibiotics are being developed.

Blood protein provides a new direction for anti-aging drugs

Omicron virus antigenic detection brings great challenges in speed and sensitivity